AstraZeneca Recentin To Start Phase III For Colorectal Cancer, But Not NSCLC
Phase II non-small cell lung cancer data on cediranib did not meet criteria for Phase III, and showed imbalance in toxicity
Phase II non-small cell lung cancer data on cediranib did not meet criteria for Phase III, and showed imbalance in toxicity